Therapeutic Plasma Exchange Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global  Therapeutic Plasma Exchange Market is Segmented By Product Type (Apheresis Machine, Filters, Others), By Indication (Neurological Disorders, Cardiovascular Disorders, Hematology Disorders, Renal Disorders, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Therapeutic Plasma Exchange Market Overview

Global  Therapeutic Plasma Exchange Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.

Therapeutic Plasma Exchange (TPE) is a procedure in which the patient’s blood is passed through an apheresis machine, where the filtered plasma is removed and discarded with reinfusion of red blood cells along with replacement fluid such as plasma or albumin into the patient. We present our experience with TPE in the treatment of various neurologic and non-neurologic diseases. Therapeutic plasma exchange (TPE), also known as plasmapheresis, removes and replaces a patient's blood plasma to treat certain diseases.

Therapeutic Plasma Exchange Market Scope

For more details of the report- Request for sample

Market Dynamics: Drivers and Restraints

Rise in the prevalence of  autoimmune diseases

Therapeutic plasma exchange is often used in the treatment of various autoimmune disorders. The rising prevalence of autoimmune diseases such as rheumatoid arthritis, lupus, and Guillain-Barré syndrome contributes to the demand for therapeutic plasma exchange.

For instance, according to Johns Hopkins University's updated factsheet, Scholars estimate that autoimmune diseases affect about 3% of the US population, or approximately 10 million people, based on published papers and primary data from smaller countries with excellent epidemiological resources, such as Scandinavian countries. This estimate is based on the current US population of 329 million.

Furthermore, the therapeutic plasma exchange market is also driven by various other factors like advancements in medical technology, rising healthcare expenditure, regulatory support and approvals and others that help the market to grow during the forecast period.

 Restraint

The cost of apheresis devices is a critical factor in determining the adoption of plasma exchange by healthcare providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component collection, while hospitals use these devices for therapeutic plasma exchange procedures. The high cost of apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance, in the US, the cost of an apheresis procedure is —USD 2,500 per treatment. Patients might not opt for these procedures owing to their high cost.

Therapeutic Plasma Exchange Segmentation

The global therapeutic plasma exchange market is segmented based on product type, indication, end-user and region.

The apheresis from the product type segment accounted for approximately 43.7% of the therapeutic plasma exchange market share.

The apheresis from the product type segment accounted for approximately 43.7% and is expected to dominate during the forecast period. The process of apheresis involves the removal of whole blood from a patient or donor. Within an instrument that is essentially designed as a centrifuge, the components of whole blood are separated. One of the separated portions is then withdrawn and the remaining components are transfused into the patient or donor.

For instance, in June 2022, Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies, stated the UK’s NHS England has selected the automated red blood cell exchange (RBCX) procedure performed on the company’s Spectra Optia Apheresis System through the NHS MedTech Funding Mandate (MTFM) to treat sickle cell disease.

Global Therapeutic Plasma Exchange Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors rise in the global prevalence of various autoimmune disorders, FDA approvals, rise in the adoption of lipoprotein apheresis treatment for cardiovascular indications like CAD, hypercholesterolemia strokes and atherosclerosis with an increased rate of cardiac deaths in recent years.

For instance, in October 2023, UCB (Euronext Brussels: UCB), a global biopharmaceutical company, stated that ZILBRYSQ (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. ZILBRYSQ can be used concomitantly with intravenous immunoglobulin and plasma exchange, without the need for supplemental dosing.

COVID-19 Impact Analysis

In the course of using TPE, the procedure was applied in diseases with similarities to COVID-19 infection, such as sepsis due to various causes, influenza infection and Secondary Hemophagocytic Lymph histiocytosis (HLH). 

Therapeutic plasma exchange has been used as an alternative treatment in severe sepsis for several decades, with conflicting results. Although there is no clear evidence to recommend plasma exchange in severe sepsis, there are a few studies supporting the role of TPE in this entity, suggesting improvement in hemodynamic stability and coagulation disbalance in septic patients receiving the treatment.

Competitive Landscape

The major global players in the market include Asahi Kasei Corporation., Baxter International Inc., Terumo Corporation., B. Braun Melsungen AG., Fresenius Kabi AG., Haemonetics Corporation, Kawasumi Laboratories, Adcem Healthcare, Kochin Inlab Equipments India Pvt Ltd, Miltenyi Biotec and among others.

Key Developments

• In January 2022, Beckman Coulter displayed its launched DxA 5000 Fit workflow-automation system at the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre. 

Why Purchase the Report?

• To visualize the global therapeutic plasma exchange market segmentation based on product type, modality, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of therapeutic plasma exchange market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global therapeutic plasma exchange market report would provide approximately 69 tables, 70 figures and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies